-
AstraZeneca: Clinical studies have shown that targeted anti-cancer drug Teresa can prolong progression free survival by more than 3 years
On June 2nd local time, AstraZeneca announced that positive results from the LAURA Phase III trial showed that Teresa (ositinib) showed statistically significant and highly clinically significant imp ...